Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDORSE trial of enarodustat versus darbepoetin alfa in hemodialysis patients with carnitine deficiency and anemia
jRCTs051250054Recruiting
- Sponsor
- Torii Pharmaceutical
- Start
- Aug 2025
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial in anaemia and end-stage kidney disease (ESKD) comparing enarodustat arm with darbepoetin alfa arm (2 arms). Primary endpoint: Hemoglobin level at 24 weeks. Started Aug 2025; status: recruiting.
02
Drugs
enarodustatdarbepoetin alfa
03
Conditions
anaemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCTs051250054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250054.